Novavax (MEX:NVAX) Short Percentage of Float


MEX:NVAX Novavax Inc MEX:NVAX
42 GF Score
Price MXN165.00
GF Value MXN65.56
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novavax Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

MEX:NVAX vs MPLT, COAG, INBX: Short Percentage of Float Comparison

For the Biotechnology subindustry, Novavax's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novavax Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novavax's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Novavax's Short Percentage of Float falls into.


MEX:NVAX
42GF Score
Novavax Inc MEX:NVAX
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novavax (MEX:NVAX) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of MXN165.00 is trading 151.7% above its estimated GF Value™ of MXN65.56. GuruFocus considers Novavax to be Significantly Overvalued.

Key valuation signals for MEX:NVAX:

  • Short Percentage of Float:
  • GF Value™: MXN65.56 vs. price of MXN165.00 (151.7% above fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the MEX:NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
42GF Score

Get the complete analysis for MEX:NVAX

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN165.00
Price
MXN65.56
GF Value